Formulation and Quality – Biomolecular
2019 PharmSci 360
All biotherapeutic modalities run a risk of inducing an immune response in treated subjects or patients. This is also true for the alternative modalities pharmaceutics, including viral vector gene therapies and cell based therapies. Risk factors, diversity of the immune responses associated with GTx and CAR-T based therapeutics will be discussed. Impurities potential to promote immune responses against some types of ATMPs will be reviewed.